Nimish Agarwal

This book will give a brief idea about the role of artificial intelligence in oral and maxillofacial surgery and its future in the field. Authors have tried to review all the studies available on this topic and presented in this book. This book will also give an idea about the pitfalls of Artificial intelligence in the field of OMFS. This book also contains information of the role of artificial intelligence in various field of surgery.

Lokale h mostatische Mittel sind n tzlich bei der Behandlung postoperativer Blutungen bei Patienten der Oralchirurgie mit angeborenen h matologischen St rungen. Lokale h mostatische Mittel sind n tzlich bei der Kontrolle von Blutungen w hrend oralchirurgischer Eingriffe bei Patienten mit angeborenen und erworbenen Blutungsst rungen und auch bei Patienten, die aufgrund ihrer systemischen Erkrankungen antithrombotische Medikamente einnehmen. Keines der derzeitigen h mostatischen Mittel erf llt alle Anforderungen. Es gibt kontinuierliche Bem hungen, neue h mostatische Mittel mit verschiedenen Verabreichungsmechanismen zur Behandlung schwerer Blutungen zu entwickeln. Dazu geh ren selbsttreibende Partikel, hydrophob modifizierte Chitosan-Gaze, injizierbare und in situ formende Gele sowie selbstexpandierende Sch ume. In Anbetracht der Sicherheitsbedenken bei einigen derzeit verwendeten h mostatischen Materialien werden immer noch effizientere und sicherere h mostatische Mittel ben tigt.

Os agentes hemost ticos locais s o teis no tratamento da hemorragia p s-operat ria em doentes de cirurgia oral com dist rbios hematol gicos cong nitos. Os agentes hemost ticos locais s o ben ficos no controlo da hemorragia durante procedimentos cir rgicos orais em doentes com doen as hemorr gicas cong nitas e adquiridas e tamb m em doentes que tomam medicamentos antitromb ticos para as suas doen as sist micas. Nenhum agente hemost tico atual satisfaz todos os requisitos. Est o a ser desenvolvidos esfor os cont nuos para desenvolver novos agentes hemost ticos com v rios mecanismos de administra o para o tratamento de hemorragias graves. Estes incluem part culas auto-propulsoras, gaze de quitosano modificada hidrofobicamente, g is inject veis e de forma o in situ e espumas auto-expans veis. Dadas as preocupa es com a seguran a de alguns materiais hemost ticos atualmente utilizados, continuam a ser necess rios agentes hemost ticos mais eficazes e mais seguros.

Gli agenti emostatici locali sono utili nella gestione del sanguinamento post-operatorio nei pazienti di chirurgia orale con disturbi ematologici congeniti. Gli agenti emostatici locali sono utili per controllare il sanguinamento durante le procedure chirurgiche orali nei pazienti con disturbi emorragici congeniti e acquisiti e anche nei pazienti che assumono farmaci antitrombotici per le loro condizioni sistemiche. Nessun agente emostatico attuale soddisfa tutti i requisiti. Sono in corso continui sforzi per sviluppare nuovi agenti emostatici con vari meccanismi di rilascio per il trattamento di emorragie gravi. Questi includono particelle autopropellenti, garze di chitosano modificate idrofobicamente, gel iniettabili e che si formano in situ e schiume autoespandenti. Dati i problemi di sicurezza di alcuni materiali emostatici attualmente utilizzati, sono ancora necessari agenti emostatici pi efficienti e sicuri.

Local hemostatic agents are useful in the management of post-operative bleeding in oral surgery patients with congenital hematologic disorders. Local hemostatic agents are beneficial in controlling bleeding during oral surgical procedures in patients with congenital and acquired bleeding disorders and also in patients who are on antithrombotic medications for their systemic conditions. No current hemostatic agents meet all the requirements. There are continuous efforts to develop new hemostatic agents with various delivery mechanisms for treating severe hemorrhage. These include self-propelling particles, hydrophobically modified chitosan gauze, injectable and in situ forming gels, and self-expanding foams. Given the safety concerns with some currently used hemostatic materials, more efficient and safer hemostatic agents are still needed.